Epidemiological aspects of Budd-Chiari in Egyptian patients: A single-center study

Table 5 Relationship between etiology and radiological findings [occluded vein(s)] in patients with Budd-Chiari syndrome

Etiology		Anatomical localization of thrombosis at presentation n (%)
		HV only	HV and PV	HV, PV and IVC	HV and IVC	IVC	χ2	P value	Sig
PC deficiency	+	3 (4.3)	0 (0.0)	0 (0.0)	1 (6.3)	0 (0.0)	0.001	0.99	NS
PS deficiency	+	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.32	0.58	NS
AT III Deficiency	+	3 (4.3)	0 (0.0)	0 (0.0)	1 (6.3)	0 (0.0)	0.001	0.99	NS
FVLM	Homo	9 (17.0)	0 (0.0)	1 (12.5)	0 (0.0)	9 (17.0)	0.03	0.85	NS
	Hetero	19 (35.8)	2 (100.0)	3 (37.5)	0 (0.0)	19 (35.8)
PGM	Homo	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	0.52	0.47	NS
	Hetero	2 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.0)
MTHFR	Homo	7 (14.0)	0 (0.0)	1 (14.3)	0 (0.0)	7 (14.0)	0.29	0.59	NS
	Hetero	19 (38.0)	0 (0.0)	3 (42.9)	1 (10.0)	19 (38.0)
JAK2 (MPD)	+	16 (31.4)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	2.08	0.15	NS
Primary APA	+	9 (12.9)	0 (0.0)	1 (33.3)	6 (37.5)	0 (0.0)	2.58	0.11	NS
Secondary APA	+	9 (12.9)	0 (0.0)	0 (0.0)	1 (6.3)	1 (33.3)	0.02	0.88	NS
Behçet’s disease	+	2 (2.9)	0 (0.0)	2 (66.7)	7 (43.8)	1 (33.3)	21.25	< 0.0001	HS
PNH	+	2 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.62	0.43	NS

Sig: Significance; NS: Not significant; HS: Highly significant; HV: Hepatic vein; PV: Portal vein; IVC: Inferior vena cava; PC: Protein C; PS: Protein S; AT: Antithrombin; FVLM: Factor V Leiden mutation; PGM: Prothrombin gene mutation; MTHFR: Methylene tetrahydrofolate reductase; JAK2: Janus tyrosine kinase-2; MPD: Myeloproliferative disorder; APA: Antiphospholipid antibody syndrome; PNH: Paroxysmal nocturnal hemoglobinuria.